DermTech

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

To revolutionize the standard of care for skin diseases by enabling precision medicine through our non-invasive, tissue-based testing platform.

To become the go-to platform for the accurate and cost-effective diagnosis, monitoring and treatment of skin diseases.

DermTech has been recognized for its innovative technology and leadership in the field of dermatology, including the 2009 Wall Street Journal Technology Innovation Award, the 2010 Project Everest Inventors Award, the 2013 Digital Health Awards, and the 2013 Edison Awards. We have also been recognized as a top innovator in the field of genomics and skin disease by organizations such as Xconomy and Fast Company.